Compare VIPS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIPS | BLTE |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.5B |
| IPO Year | 2012 | 2021 |
| Metric | VIPS | BLTE |
|---|---|---|
| Price | $16.17 | $149.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $19.83 | ★ $181.14 |
| AVG Volume (30 Days) | ★ 1.9M | 162.4K |
| Earning Date | 02-26-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $1.77 | $363.39 |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.14 | $49.00 |
| 52 Week High | $21.08 | $200.00 |
| Indicator | VIPS | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 33.37 |
| Support Level | $14.98 | $148.78 |
| Resistance Level | $16.84 | $161.28 |
| Average True Range (ATR) | 0.50 | 7.55 |
| MACD | 0.07 | -2.25 |
| Stochastic Oscillator | 59.25 | 7.40 |
Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts of 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurement, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners. As of March 31, 2025, Eric Ya Shen, chair and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds a 12.5% interest.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.